The complete eradication of Chronic Myeloid Leukemia is still challenging even in the era
of highly selective and potent BCR-ABL tyrosine kinase inhibitors (TKIs). The ‘Achilles heel’ of
TKI-based CML therapy is the inability of TKI to effectively target CML stem cells. Several pathways
have been described to induce TKI insensitiveness in quiescent CML stem cells. In this review,
we will describe the BCR-ABL/HAUSP/PML/PTEN network, whose signaling mediators converge to
regulate the function of the tumor suppressor PTEN. We will also highlight the pharmacological
strategies to modulate PTEN functions in order to sustain CML stem cell eradication.
Keywords: PTEN, PML, HAUSP, BCR-ABL, chronic myeloid leukemia.
Rights & PermissionsPrintExport